15982 Federal Register / Vol. 76, No. 55 / Tuesday, March 22, 2011 / Notices 

State of New York 

• Bronx, New York, Kings, Queens, 

and Richmond Counties 

State of Pennsylvania 

• Dauphin County 

State of Texas 

• Hunt County 

State of Virginia 

• Caroline County 

Per diem rates are published on the 

Internet at http://www.gsa.gov/perdiem 

as FTR per diem bulletins. This process 

ensures timely notice of increases or 

decreases in per diem rates established 

by GSA for Federal employees on 

official travel within CONUS. Notices 

published periodically in the Federal 

Register, such as this one, now 

constitute the only notification of 

revisions in CONUS per diem rates to 

agencies. 

Dated: March 15, 2011. 

Robert Holcombe, 

Program Director, Office of Travel, 

Transportation and Asset Management. 

[FR Doc. 2011–6659 Filed 3–21–11; 8:45 am] 

BILLING CODE 6820–14–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Meeting of the Chronic Fatigue 

Syndrome Advisory Committee 

AGENCY: Department of Health and 

Human Services, Office of the Secretary, 

Office of the Assistant Secretary for 

Health. 

ACTION: Notice. 

SUMMARY: As stipulated by the Federal 

Advisory Committee Act, the U.S. 

Department of Health and Human 

Services is hereby giving notice that the 

Chronic Fatigue Syndrome Advisory 

Committee (CFSAC) will hold a 

meeting. The meeting will be open to 

the public. 

DATES: The meeting will be held on 

Tuesday and Wednesday, May 10 and 

11, 2011. The meeting will be held from 

9 a.m. until 5 p.m. on May 10, 2011, and 

9 a.m. until 4:30 p.m. on May 11, 2011. 

ADDRESSES: Department of Health and 

Human Services; Room 800, Hubert H. 

Humphrey Building; 200 Independence 

Avenue, SW., Washington, DC 20201. 

For a map and directions to the Hubert 

H. Humphrey building, please visit 

http://www.hhs.gov/about/ 

hhhmap.html. 

FOR FURTHER INFORMATION CONTACT: 

Wanda K. Jones, DrPH; Executive 

Secretary, Chronic Fatigue Syndrome 

Advisory Committee, Department of 

Health and Human Services; 200 

Independence Avenue, SW., Hubert 

Humphrey Building, Room 712E; 

Washington, DC 20201. Please direct all 

inquiries to cfsac@hhs.gov. 

SUPPLEMENTARY INFORMATION: CFSAC 

was established on September 5, 2002. 

The Committee shall advise and make 

recommendations to the Secretary, 

through the Assistant Secretary for 

Health, on a broad range of topics 

including (1) the current state of 

knowledge and research and the 

relevant gaps in knowledge and research 

about the epidemiology, etiologies, 

biomarkers and risk factors relating to 

CFS, and identifying potential 

opportunities in these areas; (2) impact 

and implications of current and 

proposed diagnosis and treatment 

methods for CFS; (3) development and 

implementation of programs to inform 

the public, health care professionals, 

and the biomedical academic and 

research communities about CFS 

advances; and (4) partnering to improve 

the quality of life of CFS patients. 

The agenda for this meeting is being 

developed. The agenda will be posted 

on the CFSAC Web site, http:// 

www.hhs.gov/advcomcfs, when it is 

finalized. The meeting will be broadcast 

over the Internet as a real-time 

streaming video. It also will be recorded 

and archived for on demand viewing 

through the CFSAC Web site. 

Public attendance at the meeting is 

limited to space available. Individuals 

must provide a government-issued 

photo ID for entry into the building 

where the meeting is scheduled to be 

held. Those attending the meeting will 

need to sign-in prior to entering the 

meeting room. Individuals who plan to 

attend and need special assistance, such 

as sign language interpretation or other 

reasonable accommodations, should 

notify the designated contact person at 

cfsac@hhs.gov in advance. 

Members of the public will have the 

opportunity to provide oral testimony at 

the May 10–11, 2011, meeting if preregistered. Individuals who wish to 

address the Committee during the 

public comment session must preregister by Monday, April 18, 2011, via 

e-mail to cfsac@hhs.gov. Time slots for 

public comment will be available on a 

first-come, first-served basis and will be 

limited to five minutes per speaker; no 

exceptions will be made. Individuals 

registering for public comment should 

submit a copy of their oral testimony in 

advance to cfsac@hhs.gov, prior to the 

close of business on Monday, April 18, 

2011. 

If you do not submit your written 

testimony by the close of business 

Monday, April 18, 2011, you may bring 

a copy to the meeting and present it to 

a CFSAC Support Team staff member. 

Your testimony will be included in a 

notebook available for viewing by the 

public on a table at the back of the 

meeting room. 

Members of the public not providing 

public comment at the meeting who 

wish to have printed material 

distributed to CFSAC members for 

review should submit, at a minimum, 

one copy of the material to the 

Executive Secretary, at cfsac@hhs.gov, 

prior to close of business on Monday, 

April 18, 2011. Submissions are limited 

to five typewritten pages. If you wish to 

remain anonymous, please notify the 

CFSAC support team upon submission 

of your materials to cfsac@hhs.gov. 

All testimony and printed material 

submitted for the meeting are part of the 

official meeting record and will be 

uploaded to the CFSAC Web site and 

made available for public inspection. 

Testimony and materials submitted 

should not include any sensitive 

personal information, such as a person’s 

social security number; date of birth; 

driver’s license number, State 

identification number or foreign country 

equivalent; passport number; financial 

account number; or credit or debit card 

number. Sensitive health information, 

such as medical records or other 

individually identifiable health 

information, or any non-public 

corporate or trade association 

information, such as trade secrets or 

other proprietary information also 

should be excluded from any materials 

submitted. 

Dated: March 18, 2011. 

Wanda K. Jones, 

Executive Secretary, Chronic Fatigue 

Syndrome Advisory Committee. 

[FR Doc. 2011–6702 Filed 3–21–11; 8:45 am] 

BILLING CODE 4150–42–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Nominations to the Advisory 

Committee on Blood Safety and 

Availability 

AGENCY: Office of the Assistant 

Secretary for Health, Office of the 

Secretary, Department of Health and 

Human Services. 

ACTION: Notice. 

SUMMARY: The Office of Assistant 

Secretary for Health (OASH) is seeking 

nominations of qualified individuals to 

be considered for appointment as 

members of the Advisory Committee on 

Blood Safety and Availability (ACBSA). 


srobinson on DSKHWCL6B1PROD with NOTICES
Federal Register / Vol. 76, No. 55 / Tuesday, March 22, 2011 / Notices 15983 

ACBSA is a Federal advisory committee 

within the Department of Health and 

Human Services. Management support 

for the activities of this Committee is the 

responsibility of the OASH. The 

qualified individuals will be nominated 

to the Secretary of Health and Human 

Services for consideration of 

appointment as members of the ACBSA. 

Members of the Committee, including 

the Chair, are appointed by the 

Secretary. Members are invited to serve 

on the Committee for up to four-year 

terms. 

DATES: All nominations must be 

received no later than 4 p.m. EDT on 

April 22, 2011 at the address listed 

below. 

ADDRESSES: All nominations should be 

mailed or delivered to Mr. James Berger, 

Associate Public Health Advisor for 

Blood, Organ and Tissue Safety; Office 

of Assistant Secretary for Health; 

Department of Health and Human 

Services; 1101 Wootton Parkway, Suite 

250; Rockville, MD 20852. Telephone: 

(240) 453–8803. 

FOR FURTHER INFORMATION CONTACT: Mr. 

James Berger, Associate Public Health 

Advisor for Blood, Organ and Tissue 

Safety. Contact information for Mr. 

Berger is provided above. 

A copy of the Committee charter and 

roster of the current membership can be 

obtained by contacting Mr. Berger or by 

accessing the ACBSA Web site at http:// 

www.hhs.gov/bloodsafety. 

SUPPLEMENTARY INFORMATION: The 

ACBSA shall provide advice to the 

Secretary through the Assistant 

Secretary for Health. The Committee 

shall advise on a range of policy issues 

to include: (1) Definition of public 

health parameters around safety and 

availability of the blood supply and 

blood products, (2) broad public health, 

ethical and legal issues related to 

transfusion and transplantation safety, 

and (3) the implications for safety and 

availability of various economic factors 

affecting product cost and supply. 

The Committee consists of 20 voting 

members; 14 public members, including 

the Chair, and six (6) individuals 

designated to serve as official 

representative members. The public 

members are selected from State and 

local organizations, advocacy groups, 

provider organizations, academic 

researchers, ethicists, private 

physicians, scientists, consumer 

advocates, legal organizations, and from 

among communities of persons who are 

frequent recipients of blood or blood 

products. The six individuals who are 

appointed as official representative 

members are selected to serve the 

interests of the blood and blood 

products industry or professional 

organizations. The representative 

members are selected from the following 

groups: the AABB (formerly the 

American Association of Blood Banks); 

the plasma protein fraction community; 

one of the two major distributors of 

blood on a rotating basis, a trade 

organization or manufacturer of blood, 

plasma, infectious disease screening 

assays or other tissue test kits or 

equipment; and a major health care 

organization that purchases blood and 

blood products. Where more than one 

company produces a specified product 

or process, representatives from those 

companies shall rotate on the same 

schedule as public members. 

All ACBSA members are authorized 

to receive the prescribed per diem 

allowance and reimbursement for travel 

expenses that are incurred to attend 

meetings and conduct committeerelated business, in accordance with 

Standard Government Travel 

Regulations. Individuals who are 

appointed to serve as public members 

are authorized also to receive a stipend 

for attending Committee meetings and 

to carry out other Committee-related 

business. Individuals who are appointed 

to serve as representative members for a 

particular interest group or industry are 

not authorized to receive a stipend for 

the performance of these duties. 

This announcement is to solicit 

nominations of qualified candidates to 

fill four currently vacant positions on 

the ACBSA. Two candidates will fill 

public member positions as special 

government employees. In addition, two 

candidates will be representative 

members as identified in the charter. 

Nominations 

In accordance with the charter, 

persons nominated for appointment as 

members of the ACBSA should be 

among authorities knowledgeable in 

blood banking, transfusion medicine, 

plasma therapies, transfusion and 

transplantation safety, bioethics, and/or 

related disciplines. Nominations should 

be typewritten. The following 

information should be included in the 

package of material submitted for each 

individual being nominated for 

consideration of appointment: (a) The 

name, return address, daytime 

telephone number and affiliation(s) of 

the individual being nominated, the 

basis for the individual’s nomination, 

the category for which the individual is 

being nominated, and a statement 

bearing an original signature of the 

nominated individual that, if appointed, 

he or she is willing to serve as a member 

of the Committee; (b) the name, return 

address, and daytime telephone number 

at which the nominator may be 

contacted. Organizational nominators 

must identify a principal contact person 

in addition to the contact; and (c) a copy 

of a current curriculum vitae or resume 

for the nominated individual. 

Individuals can nominate themselves 

for consideration of appointment to the 

Committee. All nominations must 

include the required information. 

Incomplete nominations will not be 

processed for consideration. The letter 

from the nominator and certification of 

the nominated individual must bear 

original signatures; reproduced copies 

of these signatures are not acceptable. 

The Department is legally required to 

ensure that the membership of HHS 

Federal advisory committees is fairly 

balanced in terms of points of view 

represented and the functions to be 

performed by the advisory committee. 

Every effort is made to ensure that the 

views of women, all ethnic and racial 

groups, and people with disabilities are 

represented on HHS Federal Advisory 

committees and, therefore, the 

Department encourages nominations of 

qualified candidates from these groups. 

The Department also encourages 

geographic diversity in the composition 

of the committee. Appointment to this 

Committee shall be made without 

discrimination on the basis of age, race, 

ethnicity, gender, sexual orientation, 

disability, and cultural, religious, or 

socioeconomic status. 

The Standards of Ethical Conduct for 

Employees of the Executive Branch are 

applicable to individuals who are 

appointed as public members of Federal 

advisory committees. Individuals 

appointed to serve as public members of 

Federal advisory committees are 

classified as special government 

employees (SGEs). SGEs are government 

employees for purposes of the conflict 

of interest laws. Therefore, individuals 

appointed to serve as public members of 

the ACBSA are subject to an ethics 

review. The ethics review is conducted 

to determine if the individual has any 

interests and/or activities in the private 

sector that may conflict with 

performance of their official duties as a 

member of the Committee. Individuals 

appointed to serve as public members of 

the committee will be required to 

disclose information regarding financial 

holdings, consultancies, and research 

grants and/or contracts. 

Dated: March 15, 2011. 

James J. Berger, 

Associate Public Health Advisor for Blood, 

Organ and Tissue Safety. 

[FR Doc. 2011–6701 Filed 3–21–11; 8:45 am] 

BILLING CODE 4150–41–P 


srobinson on DSKHWCL6B1PROD with NOTICES